Braxia Scientific Corp.
Biotechnology company Beckley Psytech has welcomed neuroscience expert Dr Frank Wiegand to its team as Chief Medical Officer.
Researchers have discovered changes in the brain associated with LSD which they say could help gain insights into how the brain generates behaviour.
Biotech company, Mind Medicine Inc, is expanding its drug development pipeline with the launch of a programme to develop R(-)-MDMA for the treatment of social anxiety...
New data from the Aquilino Cancer Center Study has shown the safety and feasibility of psilocybin therapy for the treatment of depression in cancer patients.
A novel MDMA-like chemical series have been identified with drug-like properties which will be developed to treat addiction.
New data has shown that Amanita Muscaria extract (AME-1) has a potential new functional property – inhibiting human mast cell activation – which could hold promise...
A clinical trial investigating the safety and tolerability of a novel formulation of 5-MeO-DMT in psychedelic-naive subjects has dosed its first cohort of volunteers.
The first ketamine clinic in the UK has received approval from the Care Quality Commission (CQC) to begin treatments.
UK MP Crispin Blunt raised the question of rescheduling psilocybin in Parliament this week after PM Boris Johnson gave Blunt personal reassurance back in May that...
A philanthropic programme with a focus on the psychedelic sector has been launched to harness the power of innovative mental health approaches for social change.
With limited treatment options available for the condition, one company is setting out to explore the neurogenic potential of psychedelics to combat the cognitive decline of...
